Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. - Wikidata - wikimedia - TriplyDB

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

http://www.wikidata.org/entity/Q30377205

about

Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?Protection of young children from influenza through universal vaccination.Influenza Identification of critical residues in the hemagglutinin and neuraminidase of influenza virus H1N1pdm for vaccine virus replication in embryonated chicken eggs Development of live attenuated influenza vaccines against pandemic influenza strains.All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models.Continuous cell lines as a production system for influenza vaccines.Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses.Pandemic influenza vaccines - the challenges.Adverse drug events monitoring of live attenuated pandemic influenza vaccine.New technologies for influenza vaccines.The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets Passive immune neutralization strategies for prevention and control of influenza A infections.Novel viral vectored vaccines for the prevention of influenza.Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response.Understanding immunosenescence to improve responses to vaccines The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus.Molecular basis of live-attenuated influenza virus.Development of one-step real-time PCR assay for titrating trivalent live attenuated influenza vaccines.Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice.Human influenza vaccines and assessment of immunogenicity.Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.RNA replicons - a new approach for influenza virus immunoprophylaxis.Live attenuated intranasal influenza vaccine.Efficacy and safety of influenza vaccination in children with asthma.When Do Coughs and Sneezes Cause Diseases?Recombinant immunoglobulin A specific for influenza A virus hemagglutinin: production, functional analysis, and formation of secretory immunoglobulin A.Live attenuated influenza virus increases pneumococcal translocation and persistence within the middle ear.A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine.Pathogen replication, host inflammation, and disease in the upper respiratory tract.Influenza vaccines: Evaluation of the safety profile.Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

P2860

Q26783481-2152F519-BA98-45AA-B647-478F54C0EF3F Q27693242-A4E00D56-3BA7-4900-A9F5-838E3ADF3A96 Q28066188-89D4AC49-BC59-4F09-BEE9-3142C2F44099 Q28396825-DF663849-5049-4473-B3FF-5694826C0150 Q30209998-F2BFB8F9-8B81-451B-A6B5-D3CBD293AB9C Q30363730-493F2164-A6D8-4126-BA66-E45A9EE6CF1D Q30365696-4DC76881-581B-4E62-8EEE-2A774745FAED Q30371798-51075C0B-CBA4-4D48-B4B7-1F09A966271E Q30382947-2B5BD89B-FB24-45BF-8DFE-4D84220C5658 Q30389582-DDFA5585-E920-4701-8B20-C495651C2E68 Q30395088-03C65B6A-04BC-4539-8B37-64F313DB2C15 Q30408091-001F8151-3E89-46E9-8EFA-FE67DC2BE20A Q30409583-1FA11636-7C34-4A84-A544-6AFEEE8AE6DB Q30411859-2581FEC8-8B42-4AD0-95C5-067ECFC6532D Q30413023-0A9D35B3-8C37-4D33-A2D9-42E13EAED867 Q30413158-21F41F68-4018-4D60-A64A-629EDA7742EA Q30418570-DCF936D2-E94C-4102-9810-B61BB4089ED0 Q31030019-F24F31B5-6234-4D79-AE9B-98604E1AB7DA Q34281329-9998FE2B-BD6C-41C4-A568-CB54EEA2A321 Q34458066-57FBA9B2-9DA1-4588-9D20-E78D86B9C39F Q34594671-3DC5471B-767B-4BC1-B1F3-80BEF53EF2AB Q34624418-AFBB0363-5168-43CE-B05E-896DEA591D76 Q34653879-D094280F-7A69-432E-B3AC-BE0B776AD5CF Q35886506-58CA49B7-FD97-4D5E-B2FC-4871801A3B78 Q36482772-808582E5-EF6C-4610-A129-1D66C298455D Q36637886-C71C2876-4689-4B5B-B65E-9B73775DDA5C Q37621640-8173ACD5-8912-435C-95A7-AF3C531B4277 Q37812125-064E044D-9422-435C-96C5-E1A8CD015CCF Q37857257-14F39833-DA64-4560-B052-1AC2EFA78C33 Q37921281-F7F803E0-00EE-44EA-A7D4-553DF319056F Q37945198-7CCA6942-DDEE-4851-9957-94E705729370 Q37976534-D9997000-F349-4810-919D-DE68E561FDCB Q38006995-C2FFD022-4E52-4C8F-835B-4A947DAFF5CC Q39029228-68886342-D56B-4749-8C06-2E3003631B40 Q39396092-3F3D2A95-FA98-4692-9872-BE362B7D7A89 Q41600044-92B152EB-0CDA-4E48-BF97-2DDEB95FA2E0 Q41997487-209B2879-6834-4B35-AE35-DC2058AFF68C Q43237879-30E0383E-4A36-4EAF-8A76-169FB99DECB6 Q49345779-843C0555-5D24-4285-8D85-C26F828A1672 Q52725104-CA20F759-0B07-4048-B769-5B60E742D126

P2860

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

http://www.wikidata.org/entity/Q30377205

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Current status of live attenua ...... asonal and pandemic influenza.

@ast

Current status of live attenua ...... asonal and pandemic influenza.

@en

type

label

Current status of live attenua ...... asonal and pandemic influenza.

@ast

Current status of live attenua ...... asonal and pandemic influenza.

@en

prefLabel

Current status of live attenua ...... asonal and pandemic influenza.

@ast

Current status of live attenua ...... asonal and pandemic influenza.

@en

P1433

Q30377205-72D5FE1B-1849-436F-9E66-BB8DD7B80462

P1476

Q30377205-ABE1F5A8-FADB-4A1A-BE57-DC80727413A6

P2093

Q30377205-0643272C-F388-4936-AB63-9CB45E12DE25

Q30377205-3DB03EE4-BE91-49A3-BCCB-24C7AE8E0A14

P2860

Q30377205-002FCD96-F6EC-4957-AE3C-E200C3105A45

Q30377205-08C57B4A-78F2-49CD-9EE9-FC19DF21172C

Q30377205-13E7643D-CAF4-4D5F-854C-6B11A9DFA161

Q30377205-19CCDDE5-DF21-43F0-B103-383ACBC1259A

Q30377205-1E44B986-E293-4E10-81E6-A67B861C15F1

Q30377205-22D63186-1CA5-410A-BCDA-F819651014CE

Q30377205-2A05251E-1F76-46DE-9677-3842C354BD9A

Q30377205-2C9F91B8-BA9D-45AC-8BE8-E739DE22E1F9

Q30377205-2DD9A2B1-1D71-45BF-98E9-D146216D6A57

Q30377205-3020315A-D897-42F7-A8C7-B0A1D85C24A0

P304

Q30377205-76FAE8F9-6D07-475E-A158-EAE6E094B5B8

P31

Q30377205-70121AEE-E63E-4E12-A5D4-AB8857F5B01E

Q30377205-84A8C384-F0A8-4F70-AE15-9D10A6D684FF

P356

Q30377205-EFEF6171-A936-4177-AD31-C8E2CB440D5C

P433

Q30377205-7A48B4C2-C89F-4FA5-BD20-E0B45B07E095

P478

Q30377205-8A6BF42B-A2D0-409A-8286-890594E62041

P50

Q30377205-A4A774F4-D5DE-4E8E-9C25-968462BDCFF6

P577

Q30377205-DFDD1875-0E6D-49F5-A574-83B95B412EF4

P5875

Q30377205-CC8DEA90-3D8D-4317-B20A-95A877A3FA1D

P698

Q30377205-C328403C-4155-46C0-969E-482B21E223D7

P921

Q30377205-2F577530-3467-40DE-B263-C36D9F4AC561

Q30377205-4E1A85D6-C52E-40F4-B0D2-C92B0C53AA20

Q30377205-A4EF18C7-B700-487F-9C27-C4C43B25B67A

P932

Q30377205-FB920F6D-6E59-4BD5-9F65-16757C777958

P356

J.1750-2659.2008.00056.X

P1433

Influenza and Other Respiratory Viruses

P1476

Current status of live attenua ...... asonal and pandemic influenza.

@en

P2093

Catherine Luke

http://www.w3.org/2001/XMLSchema#string

Kathleen Coelingh

http://www.w3.org/2001/XMLSchema#string

P2860

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate.

Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60.

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets.

A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

P304

193-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1750-2659.2008.00056.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Christopher S Ambrose

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24438167

http://www.w3.org/2001/XMLSchema#string

P698

19453395

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

2710797

http://www.w3.org/2001/XMLSchema#string